Departments of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.
Curr Top Med Chem. 2024;24(12):1035-1049. doi: 10.2174/0115680266282360240222062032.
During the last five decades, there has been tremendous development in our understanding of cancer biology and the development of new and novel therapeutics to target cancer. However, despite these advances, cancer remains the second leading cause of death across the globe. Most cancer deaths are attributed to the development of resistance to current therapies. There is an urgent and unmet need to address cancer therapy resistance. Tetrandrine, a bis-benzyl iso-quinoline, has shown a promising role as an anti-cancer agent. Recent work from our laboratory and others suggests that tetrandrine and its derivatives could be an excellent adjuvant to the current arsenal of anti-cancer drugs. Herein, we provide an overview of resistance mechanisms to current therapeutics and review the existing literature on the anti-cancer effects of tetrandrine and its potential use for overcoming therapy resistance in cancer.
在过去的五十年中，我们对癌症生物学的理解以及针对癌症的新型治疗方法的发展取得了巨大的进展。然而，尽管取得了这些进展，癌症仍然是全球第二大致死原因。大多数癌症死亡归因于对现有治疗方法的耐药性的发展。解决癌症治疗耐药性的需求迫在眉睫。汉防己甲素是一种双苄基异喹啉，已显示出作为抗癌剂的有前途的作用。我们实验室和其他实验室的最近工作表明，汉防己甲素及其衍生物可能是当前抗癌药物武器库的极好辅助药物。在此，我们提供了对当前治疗方法耐药机制的概述，并回顾了汉防己甲素的抗癌作用及其在克服癌症治疗耐药性方面的潜在用途的现有文献。
